- GERN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $42.1 million.
- GERN has traded 1.2 million shares today.
- GERN is up 3.1% today.
- GERN was down 6.5% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in GERN with the Ticky from Trade-Ideas. See the FREE profile for GERN NOW at Trade-Ideas More details on GERN: Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Currently there are 3 analysts that rate Geron a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Geron has been 4.1 million shares per day over the past 30 days. Geron has a market cap of $603.7 million and is part of the health care sector and drugs industry. The stock has a beta of 2.89 and a short float of 20.3% with 2.44 days to cover. Shares are down 24.3% year-to-date as of the close of trading on Tuesday.